These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23750331)

  • 1. A Phase I, open-label, randomized, crossover study in three parallel groups to evaluate the effect of Rifampicin, Ketoconazole, and Omeprazole on the pharmacokinetics of THC/CBD oromucosal spray in healthy volunteers.
    Stott C; White L; Wright S; Wilbraham D; Guy G
    Springerplus; 2013 Dec; 2(1):236. PubMed ID: 23750331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I study to assess the single and multiple dose pharmacokinetics of THC/CBD oromucosal spray.
    Stott CG; White L; Wright S; Wilbraham D; Guy GW
    Eur J Clin Pharmacol; 2013 May; 69(5):1135-47. PubMed ID: 23179176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study to assess the effect of food on the single dose bioavailability of the THC/CBD oromucosal spray.
    Stott CG; White L; Wright S; Wilbraham D; Guy GW
    Eur J Clin Pharmacol; 2013 Apr; 69(4):825-34. PubMed ID: 23052407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of Orally Administered Δ9-Tetrahydrocannabinol When Coadministered With Cannabidiol on Δ9-Tetrahydrocannabinol Pharmacokinetics and Pharmacodynamics in Healthy Adults: A Randomized Clinical Trial.
    Zamarripa CA; Spindle TR; Surujunarain R; Weerts EM; Bansal S; Unadkat JD; Paine MF; Vandrey R
    JAMA Netw Open; 2023 Feb; 6(2):e2254752. PubMed ID: 36780161
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of Cytochrome P450-Mediated Cannabinoid-Drug Interactions in Healthy Adult Participants.
    Bansal S; Zamarripa CA; Spindle TR; Weerts EM; Thummel KE; Vandrey R; Paine MF; Unadkat JD
    Clin Pharmacol Ther; 2023 Sep; 114(3):693-703. PubMed ID: 37313955
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label extension study to investigate the long-term safety and tolerability of THC/CBD oromucosal spray and oromucosal THC spray in patients with terminal cancer-related pain refractory to strong opioid analgesics.
    Johnson JR; Lossignol D; Burnell-Nugent M; Fallon MT
    J Pain Symptom Manage; 2013 Aug; 46(2):207-18. PubMed ID: 23141881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.
    Langford RM; Mares J; Novotna A; Vachova M; Novakova I; Notcutt W; Ratcliffe S
    J Neurol; 2013 Apr; 260(4):984-97. PubMed ID: 23180178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTL401, a New Formulation Based on Pro-Nano Dispersion Technology, Improves Oral Cannabinoids Bioavailability in Healthy Volunteers.
    Atsmon J; Cherniakov I; Izgelov D; Hoffman A; Domb AJ; Deutsch L; Deutsch F; Heffetz D; Sacks H
    J Pharm Sci; 2018 May; 107(5):1423-1429. PubMed ID: 29287930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase I Trial to Determine the Pharmacokinetics, Psychotropic Effects, and Safety Profile of a Novel Nanoparticle-Based Cannabinoid Spray for Oromucosal Delivery.
    Lorenzl S; Gottwald F; Nistler A; Brehm L; Grötsch R; Haber G; Bremm C; Weck C; Trummer C; Brand W
    Med Cannabis Cannabinoids; 2022; 5(1):9-19. PubMed ID: 35224436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Multiple-Dose, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group QT/QTc Study to Evaluate the Electrophysiologic Effects of THC/CBD Spray.
    Sellers EM; Schoedel K; Bartlett C; Romach M; Russo EB; Stott CG; Wright S; White L; Duncombe P; Chen CF
    Clin Pharmacol Drug Dev; 2013 Jul; 2(3):285-94. PubMed ID: 27121791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of Sativex® in Dogs: Towards a Potential Cannabinoid-Based Therapy for Canine Disorders.
    Fernández-Trapero M; Pérez-Díaz C; Espejo-Porras F; de Lago E; Fernández-Ruiz J
    Biomolecules; 2020 Feb; 10(2):. PubMed ID: 32054131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration.
    Karschner EL; Darwin WD; Goodwin RS; Wright S; Huestis MA
    Clin Chem; 2011 Jan; 57(1):66-75. PubMed ID: 21078841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comprehensive Predictions of Cytochrome P450 (P450)-Mediated In Vivo Cannabinoid-Drug Interactions Based on Reversible and Time-Dependent P450 Inhibition in Human Liver Microsomes.
    Bansal S; Paine MF; Unadkat JD
    Drug Metab Dispos; 2022 Apr; 50(4):351-360. PubMed ID: 35115300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of CYP3A4 induction/inhibition on the pharmacokinetics of vilazodone in healthy subjects.
    Boinpally R; Gad N; Gupta S; Periclou A
    Clin Ther; 2014 Nov; 36(11):1638-49. PubMed ID: 25236915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Randomized, Triple-Blind, Comparator-Controlled Parallel Study Investigating the Pharmacokinetics of Cannabidiol and Tetrahydrocannabinol in a Novel Delivery System, Solutech, in Association with Cannabis Use History.
    Berl V; Hurd YL; Lipshutz BH; Roggen M; Mathur EJ; Evans M
    Cannabis Cannabinoid Res; 2022 Dec; 7(6):777-789. PubMed ID: 35787693
    [No Abstract]   [Full Text] [Related]  

  • 16. Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: an uncontrolled, open-label, 2-year extension trial.
    Rog DJ; Nurmikko TJ; Young CA
    Clin Ther; 2007 Sep; 29(9):2068-79. PubMed ID: 18035205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sativex
    Markovà J; Essner U; Akmaz B; Marinelli M; Trompke C; Lentschat A; Vila C
    Int J Neurosci; 2019 Feb; 129(2):119-128. PubMed ID: 29792372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tetrahydrocannabinol/Cannabidiol Oromucosal Spray in Patients With Multiple Sclerosis: A Pilot Study on the Plasma Concentration-Effect Relationship.
    Contin M; Mancinelli L; Perrone A; Sabattini L; Mohamed S; Scandellari C; Foschi M; Vacchiano V; Lugaresi A; Riva R
    Clin Neuropharmacol; 2018; 41(5):171-176. PubMed ID: 30024443
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
    Darwish M; Kirby M; Robertson P; Hellriegel ET
    Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.
    Liu Y; Zhou S; Wan Y; Wu A; Palmisano M
    Br J Clin Pharmacol; 2014 Nov; 78(5):1050-7. PubMed ID: 24962564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.